AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted therapy
Read the original post:
Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma
SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast to discuss the FDA approval announced earlier today at 4:15 p.m. ET, February 16, 2024.
Follow this link:
Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024
Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company’s Securities Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company’s Securities
Go here to see the original:
Lifecore Biomedical, Inc. Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal
FORT LAUDERDALE, Fla., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (“the Company”) (NASDAQ: MOTS), today announced that its special meeting of stockholders held on February 16, 2024 (the “Special Meeting”) was convened and then adjourned, without conducting any business, in order to provide stockholders additional time within which to vote on the proposal described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (the “SEC”) on January 24, 2024 (the “Proxy Statement”).
Read the rest here:
Motus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of Stockholders
BALA CYNWYD, Pa., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the closing of its previously announced underwritten public offering of 19,736,842 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 2,574,370 additional shares, at the public offering price of $8.74 per share, the closing price of its common stock on February 13, 2024. The aggregate gross proceeds to Larimar from this offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $172.5 million.
Originally posted here:
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase...
CEO, Groovy Singh appointed as a new member of the Company’s Board
Read the rest here:
BRIGHT GREEN CORPORATION ANNOUNCES CHANGES TO BOARD OF DIRECTORS
CARBIOS rallies players to promote textile circularity sector in the presence of M. Bruno Le Maire, Minister of Economy, Finance and Industrial and Digital Sovereignty
London (UK), February 19, 2024, 7:30 am CET – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, today announced promising results for its drug candidate VDA-1275 in multiple mouse cancer and human cellular organoid model of solid tumors. VDA-1275 showed statistically significant efficacy as a monotherapy, as well as synergistic effects in combination with two standard-of-care cancer treatments: sorafenib, a kinase inhibitor, and cisplatin, a widely used chemotherapy drug. The study also showed that VDA-1275 induced an immunologic response, inducing anti-tumor macrophages and memory T-cells, and inhibiting tumor-promoting macrophages. The company will present these findings on 28 February, at the Sachs 17th Annual European Life Sciences CEO Forum.
Read the rest here:
Vidac Pharma presents high efficacy in multiple solid tumor models for its next-generation cancer drug candidate and synergy with standard-of-care...
MELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational therapy FT011 for the treatment of systemic sclerosis (scleroderma), having previously granted Orphan Drug Designation.[1]
View post:
Certa Therapeutics’ FT011 Granted US FDA Fast Track for the Treatment of Systemic Sclerosis